Payment overview · 2025
General Payments
$4,217.71
164 reported records · 39 companies
Healthcare provider profile · identity verified
John J Wittman, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · RICHMOND, VA · NPI 1366412892
Verified facts
What the public records show
CMS Open Payments records show John J Wittman, M.D. received $4,217.71 in general payments during 2025 across 164 reported records.
UCB, Inc. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Epidiolex, Fintepla, Fycompa, Nayzilam, Nurtec Odt, Valtoco, Wakix, Xcopri.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Fycompa by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wakix by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Epidiolex by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Valtoco by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fintepla as an associated drug or biological on 12923 records involving 3741 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Fintepla by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $585.55 | 13.9% | 27 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $562.57 | 13.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $447.01 | 10.6% | 18 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $338.98 | 8.0% | 10 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$199.74 | 4.7% | 9 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $196.33 | 4.7% | 7 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $180.83 | 4.3% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $147.54 | 3.5% | 6 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$141.93 | 3.4% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $117.68 | 2.8% | 6 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $117.04 | 2.8% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $112.74 | 2.7% | 5 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $108.53 | 2.6% | 5 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.48 | 2.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.98 | 1.8% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $69.70 | 1.6% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $66.14 | 1.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.66 | 1.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.65 | 1.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.80 | 1.0% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $40.26 | 0.9% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.67 | 0.9% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $36.42 | 0.9% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $34.53 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.21 | 0.8% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.02 | 0.8% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $32.44 | 0.8% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $29.93 | 0.7% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $28.84 | 0.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $27.97 | 0.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.87 | 0.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.85 | 0.6% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.40 | 0.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $22.44 | 0.5% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $19.05 | 0.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.79 | 0.4% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.4% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $14.70 | 0.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $13.95 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,820.21 | 161 |
| Consulting Fee | $325.00 | 2 |
| Education | $72.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $562.57 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $259.80 | 6 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $196.33 | 7 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $187.64 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $186.14 | 11 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $182.68 | 4 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $165.02 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $151.78 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $144.94 | 7 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $141.93 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $130.64 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $117.68 | 6 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $109.57 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $108.53 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $95.57 | 4 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $89.20 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $85.48 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $75.04 | 5 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $70.49 | 8 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $66.14 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.66 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.66 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $54.45 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.65 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $40.26 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $39.93 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $37.67 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $34.53 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $34.53 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $34.02 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 117 | exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Fintepla fintepla |
2025 | Fintepla | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 19 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| WAKIX wakix |
2025 | Wakix | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
90 | 13 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Fintepla open payments reported associated product |
CMS Open Payments — General Payments 12923 supporting records · 3741 recipient NPIs · example record 1224348643 |
Fintepla · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 319 | 93 |
| Lacosamide | Lacosamide | 244 | 38 |
| Gabapentin | Gabapentin | 155 | 43 |
| Topiramate | Topiramate | 149 | 30 |
| Lamotrigine | Lamotrigine | 140 | 35 |
| Briviact | Brivaracetam | 117 | 19 |
| Levetiracetam Er | Levetiracetam | 101 | 24 |
| Xcopri | Cenobamate | 90 | 13 |
| Divalproex Sodium | Divalproex Sodium | 80 | 13 |
| Aptiom | Eslicarbazepine Acetate | 78 | suppressed |
| Carbamazepine Er | Carbamazepine | 70 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 70 | 14 |
| Lamotrigine Er | Lamotrigine | 65 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 59 | 16 |
| Trazodone Hcl | Trazodone Hcl | 59 | 13 |
| Zonisamide | Zonisamide | 51 | 11 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Fycompa | Perampanel | 45 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Vimpat | Lacosamide | 38 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 36 | suppressed |
| Phenobarbital | Phenobarbital | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Rufinamide | Rufinamide | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Clobazam | Clobazam | 27 | suppressed |
| Lamictal Xr | Lamotrigine | 25 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Fintepla | Fenfluramine Hcl | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Keppra | Levetiracetam | 19 | suppressed |
| Nayzilam | Midazolam | 19 | 15 |
| Valtoco | Diazepam | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Tegretol Xr | Carbamazepine | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Lamictal | Lamotrigine | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Wakix | Pitolisant Hcl | 14 | suppressed |
| Banzel | Rufinamide | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Depakote Er | Divalproex Sodium | 12 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,217.71 · 164 records | UCB, Inc. | AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, Dojolvi, EPIDIOLEX, FYCOMPA, Fintepla, Gamunex-C, Gocovri, INGREZZA, KESIMPTA, LEQEMBI, LUMRYZ, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, POCKET EEG DEVICE, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, Qelbree, REXULTI, Rystiggo, SKYCLARYS, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYVGART, VYVGART HYTRULO, WAINUA, WAKIX, XCOPRI, XYWAV, Xeomin, ZAVZPRET, ZEPBOUND, ZEPOSIA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CATALYST PHARMACEUTICALS, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error